BeGraft aortic stent:一项欧洲多中心经验报告了先天性心脏病血管狭窄治疗的急性安全性和有效性

IF 18 Q4 Medicine
G. Butera , M. Remonato , M. Pilati , M. Jones , M. Carminati , S. Hascoet , L. Giugno , P. Betrian , A.E. Baruteau , E. Pascall , H. Lucron , G. Milani
{"title":"BeGraft aortic stent:一项欧洲多中心经验报告了先天性心脏病血管狭窄治疗的急性安全性和有效性","authors":"G. Butera ,&nbsp;M. Remonato ,&nbsp;M. Pilati ,&nbsp;M. Jones ,&nbsp;M. Carminati ,&nbsp;S. Hascoet ,&nbsp;L. Giugno ,&nbsp;P. Betrian ,&nbsp;A.E. Baruteau ,&nbsp;E. Pascall ,&nbsp;H. Lucron ,&nbsp;G. Milani","doi":"10.1016/j.acvdsp.2023.07.024","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p><span><span>Stent implantation for the treatment of vessel stenosis in </span>congenital heart diseases has become the preferred method of treatment. Availability of new covered stents may decrease complications and may have an important role in the management of patients with complex </span>anatomy.</p></div><div><h3>Objective</h3><p>The aim of this study was to evaluate the feasibility and safety of the pre-mounted cobalt-chromium stent-graft covered ePTFE Aortic BeGraft in a broad spectrum of congenital vascular lesions.</p></div><div><h3>Methods</h3><p>A retrospective study of 112 implanted Be Graft Aortic stents between 2016 and 2022 in six different European centers was performed.</p></div><div><h3>Results/Expected results</h3><p><span><span><span>One hundred four patients with mean age 13 years (range 1–70 years; 56.5 kg, range 11–115 kg) underwent BeGraft stent implantation. Seventy three patients had aortic coarctation, seven BeGraft stents were implanted </span>in patients<span><span> with Fontan circulation for either restoration of Fontan conduit<span> patency in three patients and fenestration closure in four). Fourteen BeGraft aortic stents were implanted in 12 patients with dysfunctional RVOT. Eleven patients with complex CHD had miscellaneous indications for stent implantation: </span></span>superior vena cava stenosis in 3 patients, rehabilitation of percutaneous </span></span>Potts shunt<span> in two patients, exclusion of a porto-caval fistula<span> in one patient, relief of pulmonary arteries stenosis in 3 patients and percutaneous PA debanding in two patients with ccTGA. All the stents were implanted successfully. Median stent diameter was 16</span></span></span> <!-->mm (range 7–24<!--> <span>mm). Major complications were the following: one aortic dissection<span><span>, 2 stent balloon rupture, 1 patient experienced a cerebral embolization<span> without neurological consequences and 1 patient had a femoral artery occlusion requiring </span></span>vascular surgery.</span></span></p></div><div><h3>Conclusion/Perspectives</h3><p>BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the long term follow up still needs to be investigated given its recent introduction into clinical practice.</p></div>","PeriodicalId":8140,"journal":{"name":"Archives of Cardiovascular Diseases Supplements","volume":null,"pages":null},"PeriodicalIF":18.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BeGraft aortic stents: A European multi-centre experience reporting acute safety and efficacy outcomes for the treatment of vessel stenosis in congenital heart diseases\",\"authors\":\"G. Butera ,&nbsp;M. Remonato ,&nbsp;M. Pilati ,&nbsp;M. Jones ,&nbsp;M. Carminati ,&nbsp;S. Hascoet ,&nbsp;L. Giugno ,&nbsp;P. Betrian ,&nbsp;A.E. Baruteau ,&nbsp;E. Pascall ,&nbsp;H. Lucron ,&nbsp;G. Milani\",\"doi\":\"10.1016/j.acvdsp.2023.07.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p><span><span>Stent implantation for the treatment of vessel stenosis in </span>congenital heart diseases has become the preferred method of treatment. Availability of new covered stents may decrease complications and may have an important role in the management of patients with complex </span>anatomy.</p></div><div><h3>Objective</h3><p>The aim of this study was to evaluate the feasibility and safety of the pre-mounted cobalt-chromium stent-graft covered ePTFE Aortic BeGraft in a broad spectrum of congenital vascular lesions.</p></div><div><h3>Methods</h3><p>A retrospective study of 112 implanted Be Graft Aortic stents between 2016 and 2022 in six different European centers was performed.</p></div><div><h3>Results/Expected results</h3><p><span><span><span>One hundred four patients with mean age 13 years (range 1–70 years; 56.5 kg, range 11–115 kg) underwent BeGraft stent implantation. Seventy three patients had aortic coarctation, seven BeGraft stents were implanted </span>in patients<span><span> with Fontan circulation for either restoration of Fontan conduit<span> patency in three patients and fenestration closure in four). Fourteen BeGraft aortic stents were implanted in 12 patients with dysfunctional RVOT. Eleven patients with complex CHD had miscellaneous indications for stent implantation: </span></span>superior vena cava stenosis in 3 patients, rehabilitation of percutaneous </span></span>Potts shunt<span> in two patients, exclusion of a porto-caval fistula<span> in one patient, relief of pulmonary arteries stenosis in 3 patients and percutaneous PA debanding in two patients with ccTGA. All the stents were implanted successfully. Median stent diameter was 16</span></span></span> <!-->mm (range 7–24<!--> <span>mm). Major complications were the following: one aortic dissection<span><span>, 2 stent balloon rupture, 1 patient experienced a cerebral embolization<span> without neurological consequences and 1 patient had a femoral artery occlusion requiring </span></span>vascular surgery.</span></span></p></div><div><h3>Conclusion/Perspectives</h3><p>BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the long term follow up still needs to be investigated given its recent introduction into clinical practice.</p></div>\",\"PeriodicalId\":8140,\"journal\":{\"name\":\"Archives of Cardiovascular Diseases Supplements\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":18.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Cardiovascular Diseases Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1878648023002458\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878648023002458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

导读支架植入术治疗先天性心脏病血管狭窄已成为首选的治疗方法。新的覆盖支架的可用性可能会减少并发症,并可能在复杂解剖结构患者的管理中发挥重要作用。目的评估预安装钴铬支架覆盖ePTFE主动脉瓣在广谱先天性血管病变中的可行性和安全性。方法回顾性分析2016年至2022年在欧洲6个不同中心植入的112例Be瓣主动脉支架。结果/预期结果104例患者,平均年龄13岁(范围1-70岁;56.5公斤,范围11-115公斤)接受了BeGraft支架植入术。73例患者主动脉缩窄,其中3例为恢复Fontan导管通畅,4例为关闭开窗,7例为Fontan循环患者植入BeGraft支架。在12例RVOT功能不全患者中植入14个BeGraft主动脉支架。11例复杂冠心病患者支架植入术指征繁杂:3例上腔静脉狭窄,2例经皮Potts分流康复,1例门静脉瘘排除,3例肺动脉狭窄缓解,2例ccTGA经皮PA去带。所有支架均成功植入。支架中位直径为16mm(范围7 - 24mm)。主要并发症如下:1例主动脉夹层,2例支架球囊破裂,1例无神经系统后果的脑栓塞,1例需要血管手术的股动脉闭塞。结论/观点begraft支架可以安全有效地用于广泛的先天性心脏病。这些良好的结果是否会在长期随访中稳定仍需要调查,因为它最近被引入临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
BeGraft aortic stents: A European multi-centre experience reporting acute safety and efficacy outcomes for the treatment of vessel stenosis in congenital heart diseases

Introduction

Stent implantation for the treatment of vessel stenosis in congenital heart diseases has become the preferred method of treatment. Availability of new covered stents may decrease complications and may have an important role in the management of patients with complex anatomy.

Objective

The aim of this study was to evaluate the feasibility and safety of the pre-mounted cobalt-chromium stent-graft covered ePTFE Aortic BeGraft in a broad spectrum of congenital vascular lesions.

Methods

A retrospective study of 112 implanted Be Graft Aortic stents between 2016 and 2022 in six different European centers was performed.

Results/Expected results

One hundred four patients with mean age 13 years (range 1–70 years; 56.5 kg, range 11–115 kg) underwent BeGraft stent implantation. Seventy three patients had aortic coarctation, seven BeGraft stents were implanted in patients with Fontan circulation for either restoration of Fontan conduit patency in three patients and fenestration closure in four). Fourteen BeGraft aortic stents were implanted in 12 patients with dysfunctional RVOT. Eleven patients with complex CHD had miscellaneous indications for stent implantation: superior vena cava stenosis in 3 patients, rehabilitation of percutaneous Potts shunt in two patients, exclusion of a porto-caval fistula in one patient, relief of pulmonary arteries stenosis in 3 patients and percutaneous PA debanding in two patients with ccTGA. All the stents were implanted successfully. Median stent diameter was 16 mm (range 7–24 mm). Major complications were the following: one aortic dissection, 2 stent balloon rupture, 1 patient experienced a cerebral embolization without neurological consequences and 1 patient had a femoral artery occlusion requiring vascular surgery.

Conclusion/Perspectives

BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the long term follow up still needs to be investigated given its recent introduction into clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Cardiovascular Diseases Supplements
Archives of Cardiovascular Diseases Supplements CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
508
期刊介绍: Archives of Cardiovascular Diseases Supplements is the official journal of the French Society of Cardiology. The journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles, editorials, and Images in cardiovascular medicine. The topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Additionally, Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信